Aerpio Pharmaceuticals, Inc. Banner Image

Aerpio Pharmaceuticals, Inc. has reached its limit for free report views

Work for Aerpio Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Aerpio Pharmaceuticals, Inc.

  • Ticker ARPO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aerpio Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Cincinnati, Ohio
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome ("ARDS") associated with COVID-19 infections. Recently publishedMore mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemm's canal, a critical component of the conventional outflow tract. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"), is being developed as a potential treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications.. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS).
4.8 / 5.0 (284)

Aerpio Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 284 reviews.

Aerpio Pharmaceuticals, Inc.

Most Recent Annual Report

Aerpio Pharmaceuticals, Inc.
MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Aerpio Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Aerpio Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!